Literature DB >> 30137117

Survival analysis of penile cancer patients treatedat a tertiary oncology hospital.

Marco Antônio Comper de Souza1, Sérgio Riguete Zacchi1, Katia Cirlene Gomes Viana2, Camila Brandão de Souza3, Eliana Zandonade1, Maria Helena Costa Amorim1.   

Abstract

This article aims to estimate the specific survival of patients with penile cancer treated at a state tertiary oncology hospital. The study included 100 cases incidents patients with penile cancer treated at a cancer center, from 2000 to 2011, follow-up to December 31, 2012. The hospital-based cancer registry and medical records were used as data sources. We used the Kaplan-Meier method to estimate survival and the Cox model was used to assess prognostic factors. All had histology for penile cancer as a basis for diagnosis. For location of the 75% tumor were not specified, followed by 18% located in the glans, 04% in the foreskin. The median survival time was 49 months, 89% presented themselves between stages I and II. Patients with rural occupations had a mean survival time of 75.02 months, patients with non-rural occupations 42.14 months; Patients residing in metropolitan area - Espírito Santo had a mean survival time of 26.03 months, other patients 71.42 months; In patients with compromised lymph nodes, the mean survival time was 30.59 months, and in patients with no compromised lymph nodes, the mean survival time was 75.83 months. This study demonstrates reduced survival in non-rural workers who reside in metropolitan area and who present with compromised lymph nodes and metastasis.

Entities:  

Mesh:

Year:  2018        PMID: 30137117     DOI: 10.1590/1413-81232018238.17692016

Source DB:  PubMed          Journal:  Cien Saude Colet        ISSN: 1413-8123


  1 in total

1.  Competing-risks model for predicting the prognosis of penile cancer based on the SEER database.

Authors:  Jin Yang; Zhenyu Pan; Yujing He; Fanfan Zhao; Xiaojie Feng; Qingqing Liu; Jun Lyu
Journal:  Cancer Med       Date:  2019-10-27       Impact factor: 4.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.